Intra-Abdominal Candidiasis in Cancer Patients: A 10-Year Experience in a Middle-Income Country
- PMID: 39455432
- DOI: 10.1111/myc.13807
Intra-Abdominal Candidiasis in Cancer Patients: A 10-Year Experience in a Middle-Income Country
Abstract
Background: Invasive candidiasis (IC) represents a significant threat to both mortality and morbidity, especially among vulnerable populations. Intra-abdominal candidiasis (IAC) frequently occurs in critically ill and cancer patients, with these specific groups carrying a heightened risk for such invasive fungal infections. Despite this, there is a noticeable lack of attention to IAC in cancer patients within the literature, highlighting a critical gap that requires urgent consideration.
Objectives: This study aimed to explore the clinical and epidemiological characteristics of IAC and identify prognostic factors in a cancer centre in a middle-income country over 10 years.
Patients/methods: A retrospective cohort observational study of adults diagnosed with IAC was conducted at the Instituto do Cancer do Estado de São Paulo (ICESP), a tertiary hospital specialising in oncological diseases with 499 beds, including 85 intensive care unit (ICU) beds, from December 2009 through May 2021.
Results: A total of 128 episodes were included: 67.2% admitted to the ICU; 54.7% males; and median age 62 years. The predominant diagnosis was peritonitis (75.8%). Blood culture samples were collected from 128 patients upon admission, revealing candidemia in 17.2% (22). The most frequently isolated were C. albicans (n = 65, 50.8%) and C. glabrata (n = 42, 32.8%). Antifungal treatment was administered to 91 (71%) patients, with fluconazole (64.8%) and echinocandins (23.4%) being the most common choices. A significant proportion of these patients had a history of abdominal surgery or antibiotic use. Independent factors associated with 30-day mortality included the median Sequential Organ Failure Assessment (SOFA) score of 6 (OR = 1.30, 95% CI 1.094-1.562, p = 0.003), days of treatment (median 10.5) (OR = 0.93, 95% CI 0.870-0.993, p = 0.031) and abdominal source control (78.1%) (OR = 0.148, 95% CI 0.030-0.719, p = 0.018). The 30-day mortality rate was 41.1%.
Conclusions: Our study underscores the critical importance of implementing effective source control as a key strategy for reducing mortality in IAC.
Keywords: Candida peritonitis; abdominal candidiasis; cancer; invasive candidiasis.
© 2024 Wiley‐VCH GmbH. Published by John Wiley & Sons Ltd.
References
-
- J. Delaloye and T. Calandra, “Invasive Candidiasis as a Cause of Sepsis in the Critically Ill Patient,” Virulence 5, no. 1 (2014): 161–169.
-
- C. Lass‐Flörl, S. S. Kanj, N. P. Govender, G. R. Thompson, L. Ostrosky‐Zeichner, and M. A. Govrins, “Invasive Candidiasis,” Nature Reviews. Disease Primers 10, no. 1 (2024): 20.
-
- M. Bassetti, D. R. Giacobbe, C. Agvald‐Ohman, et al., “Invasive Fungal Diseases in Adult Patients in Intensive Care Unit (FUNDICU): 2024 Consensus Definitions From ESGCIP, EFISG, ESICM, ECMM, MSGERC, ISAC, and ISHAM,” Intensive Care Medicine 50, no. 4 (2024): 502–515.
-
- B. J. Kullberg and M. C. Arendrup, “Invasive Candidiasis,” New England Journal of Medicine 373, no. 15 (2015): 1445–1456.
-
- J. L. Vincent, J. Rello, J. Marshall, et al., “International Study of the Prevalence and Outcomes of Infection in Intensive Care Units,” JAMA 302, no. 21 (2009): 2323–2329.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
